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anagawa, Japan
OBJECTIVES We examined the lytic effects of anti-glycoprotein (GP) IIb/IIIa agents on platelet thrombi
formed on the collagen surface under blood flow conditions.
BACKGROUND Anti-GP IIb/IIIa agents may influence platelet thrombi already formed.
METHODS Blood samples were anticoagulated either by the specific antithrombin Argatroban (100 M)
or by unfractionated heparin (0.1 U/ml). After platelet thrombi were formed on a collagen
surface following 6-min perfusion of whole blood obtained from eight adult donors
containing fluorescinated platelets at a wall shear rate of 1,500 s1, additional blood samples
from the same donors either containing or not containing anti-GP IIb/IIIa agents
(abciximab, eptifibatide, or tirofiban) were perfused on these thrombi. The three-dimensional
structures of the platelet thrombi were continuously observed by laser confocal microscopy
equipped with a piezo-electric motor control unit and recorded.
RESULTS The platelet thrombi started to dissolve after perfusion of blood containing the anti-GP
IIb/IIIa agents, whereas their growth resumed after subsequent perfusion of control blood.
Only a single layer of platelets having heights of 3  1 m, 3  2 m, and 3  1 m,
respectively, could be seen after 6-min perfusion of blood containing abciximab, eptifibatide,
and tirofiban, whereas the initial height of the platelet thrombi of 8  2 m increased to 11
 4 m after subsequent perfusion of control blood (n  8). The volume of the platelet
thrombi, which was 3,352  1,045 m3 before starting the second perfusion, was reduced to
778  102 m3, 812  122 m3, and 856  144 m3 after 6-min perfusion of blood
containing abciximab, eptifibatide, and tirofiban, respectively.
CONCLUSIONS We have shown in this study that anti-GP IIb/IIIa agents possess the ability to dissolve
platelet thrombi. (J Am Coll Cardiol 2004;44:316–23) © 2004 by the American College of
Cardiology Foundationf
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pt is now well known that agents blocking the platelet
lycoprotein (GP) IIb/IIIa receptor (integrin IIb3) re-
uce the incidence of early thrombotic complications after
ngioplasty (1– 8) and prevent death and myocardial
nfarction in patients with acute coronary syndromes (8).
nti-glycoprotein IIb/IIIa agents have been reported to
nhibit platelet aggregation induced by chemical activation
9,10) or by shearing (11), and to inhibit platelet
See page 324
hrombus formation in animal models of endothelial dam-
ge (12). In addition to these effects, several previous clinical
nd animal studies have reported that the anti-GP IIb/IIIa
gents enhance the reperfusion rate after administration of
brinolytic agents and may even induce spontaneous reper-
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Manuscript received October 29, 2003; revised manuscript received January 16,s004, accepted February 24, 2004.usion (13–18), although the effect was not marked when
he dose of fibrinolytic agent was reduced to half (19). These
ndings led us to wonder whether anti-GP IIb/IIIa agents
ight also have the potential to augment thrombolysis or
nduce thrombolysis by themselves, in addition to their
ell-known preventive effect on thrombus formation.
Previously, platelet aggregation induced by chemical ago-
ists, such as adenosine diphosphate or thrombin, was
eported to disaggregate when the binding capacity of GP
Ib/IIIa was affected (20,21). However, this experimental
nding may or may not be relevant to the question of
nhanced thrombolysis induced by these agents in vivo,
ecause the mechanism of platelet thrombus formation in
ivo, especially under high shear stress conditions, might
ot be the same as that underlying platelet aggregation in
itro (22,23). Multiple receptor-ligand interactions, includ-
ng von Willebrand factor (VWF) binding to both GP Ib
nd GP IIb/IIIa, are involved in the former (22,23),
hereas the latter is exclusively mediated by fibrinogen
inding to activated GP IIb/IIIa (9). In the present study,
e found that the anti-GP IIb/IIIa agents available for
linical use, namely, abciximab, eptifibatide, and tirofiban,
ot only inhibit platelet thrombus formation on a collagen
urface under blood flow conditions but also have the
otential to dissolve platelet thrombi already formed on the
urface. These results may explain why these anti-GP
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July 21, 2004:316–23 Thrombus Dissolution by Anti-GP IIb/IIIaIb/IIIa agents augment the thrombolytic effects of fibrino-
ytic agents or induce spontaneous reperfusion by them-
elves.
ETHODS
ample preparation. The anti-GP IIb/IIIa agents used in
his study were abciximab (ReoPro; Centocor, Malvern,
ennsylvania), eptifibatide (Integrellin; Cor Therapeutic,
nc., San Francisco, California) and tirofiban (Aggrastat;
erck & Co., Inc., West Point, Pennsylvania), all of which
re available for clinical use in many countries (24). Venous
lood from eight normal volunteers abstaining from any
ype of medication was drawn through 19-G needles into
lastic syringes containing one-tenth of their volume of the
pecific thrombin inhibitor Argatroban (Mitsubishi Kagaku,
okyo, Japan) (25) or by commonly used anticoagulant of
eparin. The final concentrations of the anticoagulant used
ere 100 M for Argatroban and 0.1 U/ml for heparin.
rgatroban, instead of the more commonly used anticoag-
lant citrate, was used for anticoagulation, to avoid pleio-
ropic effects through decreased cation concentration. Hep-
rin, although used commonly in the clinical setting, was
sed only to show the relevance of the results obtained with
rgatroban, because it may influence the results by either
ctivating the platelets or modifying the interaction between
WF and GPIb (22). Platelets in whole blood were
endered fluorescent by the addition of mepacrine (Sigma
o. Ltd., St. Louis, Missouri), according to a previously
stablished procedure (25).
reparation of the flow chamber and visualization of the
latelet thrombi. Acid-insoluble fibrillar type I collagen
rom bovine Achilles tendon (Sigma Co.) was immobilized
n a glass coverslip (Corning Inc., Acton, Massachusetts; 24
m  50 mm) in a parallel-plate flow chamber (25). The
istance between the two glass plates was fixed at 220 m
y the placement of a silicon gasket. Then, the blood
amples were introduced into the chamber with a syringe
ump (Harvard Apparatus Co. Ltd., Holliston, Massachu-
etts) at a constant flow rate to achieve a wall shear rate of
,500 s1. Platelet thrombi forming on the surface of
ollagen were visualized with an inverted stage epi-
uorescence video-microscope system equipped with a
80-nm excitation light source (DM IRB, 1RB-FLUO;
eica, Wetzlar, Germany) (25). The microscopic images
ere digitized online with a photosensitive color charge-
oupled device camera (L-600; Leica) and stored as digital
mages in a personal computer (Power Macintosh G4;
pple Co. Ltd., Palo Alto, California). To quantify the
Abbreviations and Acronyms
GP  glycoprotein
NIH  National Institutes of Health
VWF  von Willebrand factorercentage surface area coverage by the platelets, the digital solor images were converted into black-and-white images
sing the National Institutes of Health (NIH) Image
oftware (public domain software by Dr. Wayne Rasband,
IH, version 1.62), and the percentage surface area cover-
ge by the platelets was calculated.
To detect the effects of anti-GP IIb/IIIa agents of
issolving platelet thrombi formed on the collagen surface,
hree-dimensional structural analysis was conducted using
n ultra-fast laser confocal microscope equipped with a
iezo-electric motor control unit (Fig. 1A). Using a confo-
al unit composed of a rapidly rotating disk having 20,000
inholes and micro lenses on it (CSU10; Yokogawa Med-
cal Co., Tokyo, Japan), each confocal image could be
btained within 10 ms (26). To visualize the three-
imensional structure of the platelet thrombi formed on the
ollagen surface, the objective lenses were up and down (20
m/50 s) at a constant speed controlled by a piezo-electric
otor control system, so that scanning images of the
hrombi were obtained. The confocal images were enhanced
sing an image intensifier (SRUB GEN III, Solamer, Salt
ake City, Utah, and Intermedical Co., Tokyo, Japan), and
he intensified images were stored in a digital video recorder
HandyCum; Sony Co., Tokyo, Japan) and transferred to a
ersonal computer (Power Macintosh G4, Apple Co. Ltd.).
hree-dimensional projection images of the thrombi were
btained using shareware NIH images, as previously re-
orted (26). For quantification, the cross-sectional area
overed by platelets was calculated at the base and 3, 6, and
m above the base of the platelet thrombi. The results
ere expressed as a percentage of the area covered at the
ase of the thrombi. The volume of the platelet thrombi was
alculated by z-section integration of the cross-sectional
rea in each micrometer.
xperimental protocol. Experiments were performed as
escribed in Figure 1B and its legend. Briefly, 15 ml of
lood samples either containing or not containing anti-GP
Ib/IIIa agents at concentrations sufficient enough to inhibit
latelet thrombus formation on the collagen surface (abcix-
mab: 10 g/ml; eptifibatide and tirofiban: 0.5 M) was
erfused on the same collagen surface on which platelet
hrombi were already formed by the initial 15 ml of control
lood perfusion. The second perfusion, of blood either
ontaining or not containing the anti-GP IIb/IIIa agents,
as started immediately after the first perfusion was com-
leted, without stopping the blood flow, to avoid the falling
f leukocytes onto the platelet thrombi because of gravity, as
t is speculated that the presence of leukocytes may influence
he stability of the platelet thrombi. The three-dimensional
tructures of the platelet thrombi were assessed every 50 s by
he three-dimensional imaging technique described earlier.
ll the experiments were performed at room temperature,
ontrolled between 22°C to 26°C.
tatistical analysis. All numerical results were presented as
ean  SD, unless otherwise stated. The effects of various
oncentrations of the three anti-GP IIb/IIIa agents under
tudy on the percentage surface area coverage by the
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Thrombus Dissolution by Anti-GP IIb/IIIa July 21, 2004:316–23latelets were tested by two-way analysis of variance. The
ffects of the second perfusion of blood containing one of
he various anti-GP IIb/IIIa agents on the volume and
aximum height of the platelet thrombi already formed
ere also tested by one-way analysis of variance. The
ifferences between groups of data were assessed by
ewman-Keuls test. A p value of 0.05 was considered to
enote statistical significance.
ESULTS
ffect of anti-GP IIb/IIIa agents on platelet thrombus
ormation on the collagen surface. All the anti-GP IIb/
IIa agents tested in our study inhibited platelet thrombus
ormation on the collagen surface in a dose-dependent manner
o matter whether blood was anticoagulated with Argatroban
r heparin (Fig. 2). There were no statistically significant
ifferences between the effects of abciximab and eptifibatide, or
etween those of eptifibatide and tirofiban. On the other hand,
he percentage surface area coverage of 7.7  2.6% achieved
ith tirofiban at a dose yielding the maximum inhibitory effect
0.5 M) was significantly higher than that of 4.6  2.2%
chieved with the maximum inhibitory dose of abciximab
10 g/ml; p  0.05). Only one layer of attached platelets,
ithout z-section growth mediated by platelet cohesion, was
bserved after perfusion of blood containing abciximab
10 g/ml), eptifibatide (0.5 M), or tirofiban (0.5 M),
hereas three-dimensional growth mediated by platelet cohe-
ion was observed in the absence of these agents (Fig. 3).
ffect of anti-GP IIb/IIIa agents on platelet thrombi
ormed on the collagen surface. Soon after blood contain-
ng any one of the anti-GP IIb/IIIa agents began to be
erfused over the collagen surface where platelet thrombi had
ormed, the thrombi started to dissolve no matter whether
lood was anticoagulated by Argatroban or heparin. On the
ther hand, the platelet thrombi continued to grow after
igure 2. Effects of anti-glycoprotein (GP) IIb/IIIa agents on platelet
hrombus formation on the collagen surface under blood flow conditions.
ifteen ml of blood containing fluorescent platelets were perfused on the
ollagen surface for 6 min, either in the presence or absence of the anti-GP
Ib/IIIa agents abciximab, eptifibatide, and tirofiban at the final concen-
rations shown in the figure. The results shown represent the mean and
tandard deviation of the eight sets of replicated experiments. The * and
* indicate values significantly lower than those in the absence of the
nti-GP IIb/IIIa agents with the p value 0.05 and 0.01, respectively.igure 1. Experimental protocol. Fifteen ml of blood anticoagulated either
y Argatroban or heparin containing platelets rendered fluorescent by the
ddition of mepacrine was perfused in a parallel-plate flow chamber
omposed of two glass plates, one of which was covered by immobilized
ype I collagen. A perfusion of an additional 15 ml of blood obtained from
he same donors and treated by the same procedure, containing or not
ontaining one of the anti-glycoprotein (GP) IIb/IIIa agents, was imme-
iately started to perfuse on the same collagen surface for the same length
f time (B). The two-dimensional and three-dimensional structures of the
latelet thrombi formed on the collagen surface were continually assessed
y fluorescence microscopy or by a laser confocal microscope controlled by
piezo-electric motor control system (A). In a laser confocal imaging
ystem, the platelet thrombi were scanned from the bottom to the top (a’)
t a constant speed by controlling the position of objective lens (a) by
iezo-motor control unit. Then, the scanning confocal images were
rojected from the top to the bottom at every 5° to obtain three-
imensional projection images, including projections from the top, 45°
osition from the horizontal axis and the side of the platelet thrombi,
hich are shown in Figures 3 and 4. The maximum height of the platelet
hrombi (h) was calculated based on the projection image from the side of
he platelet thrombi. ubsequent perfusion of blood not containing any of the
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July 21, 2004:316–23 Thrombus Dissolution by Anti-GP IIb/IIIanti-GP IIb/IIIa agents. Not only single platelets, but also
asses of platelet thrombi became detached from the body of
he thrombi when blood containing an anti-GP IIb/IIIa agent
as perfused. Three-dimensional analysis of the thrombi
evealed that both the height and the volume of the platelet
hrombi began to decrease owing to dissolution of platelet
ohesion (Figs. 4 and 5). The maximum height as well as the
olume of the platelet thrombi immediately before and after
ompletion of perfusion of blood containing one of the
nti-GP IIb/IIIa agents, abciximab (10 g/ml), eptifibatide
0.5 M), or tirofiban (0.5 M), are summarized in Table 1.
ndeed, the maximum height of the thrombi and their volume
ecreased significantly after 6-min perfusion of blood contain-
ng one of the anti-GP IIb/IIIa agents.
Three-dimensional imaging revealed only a single layer of
latelets remained after 6-min perfusion of blood contain-
ng one of the anti-GP IIb/IIIa agents (Fig. 5). There were
o differences in the effects on the platelet thrombi among
bciximab, eptifibatide, and tirofiban.
ISCUSSION
nti-GP IIb/IIIa agents were developed as antiplatelet agents,
ased on the premise that they would block platelet aggrega-
igure 3. Effects of anti-glycoprotein (GP) IIb/IIIa agents on three-dim
erformed as described in the legend for Figure 2, but the platelet thromb
op (A), 45° position from the horizontal axis (B), and the side (C) are sho
left panel), whereas only a single layer of attached platelets was seen in t
.5 M eptifibatide, and tirofiban). The results shown are representative o
imilar to those obtained with abciximab and tirofiban, but are not shown
lood was anticoagulated by heparin. For the accompanying videos corres
t www.cardiosource.com/jacc.html.ion (7–9). Clinical experiences, as well as animal experiments, rave demonstrated that early reperfusion of coronary arteries
an be induced by the administration of anti-GP IIb/IIIa
gents, regardless of whether or not fibrinolytic agents were
lso administered concomitantly (13–19). We showed that the
idely used GP IIb/IIIa antagonists abciximab, eptifibatide,
nd tirofiban have the potential to dissolve platelet thrombi
ormed on a collagen surface. We postulate that the effect of
hese agents of dissolving platelet thrombi already formed, in
ddition to their preventive effect on de novo platelet thrombus
ormation, contributes to the reportedly augmented thrombo-
ytic effects observed when these agents are administered in
ombination with fibrinolytic agents, and to the increased rate
f reperfusion achieved when these agents are used alone
13–19).
Unlike in the case of platelet aggregation induced by
hemical agonists, which is known to be mediated exclu-
ively by fibrinogen binding to activated GP IIb/IIIa,
latelet thrombus formation on the collagen surface require
timulation of several platelet receptors induced by their
inding of the corresponding ligands, including the GP
b-VWF interaction (27–29), GP IIb/IIIa ligation by
lasma proteins including fibrinogen and VWF (27–29),
2Y1 and P2Y12 stimulation by adenosine diphosphate
al platelet thrombus growth on the collagen surface. Experiments were
visualized by laser confocal microscopy. The projection images from the
hree-dimensional platelet thrombus growth occurred in the control group
sence of any of the anti-GP IIb/IIIa agents tested (10 g/ml abciximab,
results of eight replicated experiments. The results with eptifibatide were
se of space limitation. There were no differences in the results when the
ng to Figure 3 (Videos 1, 2, and 3), please see the July 21 issue of JACCension
i were
wn. T
he pre
f the
becau
pondieleased from activated platelets (30,31), are involved in
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Thrombus Dissolution by Anti-GP IIb/IIIa July 21, 2004:316–23latelet cohesion under high shear stress conditions. Al-
hough numerous receptor-ligand interactions, such as the
nitial tethering mediated by VWF-GP Ib interaction,
ay play a role in the formation of platelet thrombi, our
resent findings suggest that GP IIb/IIIa ligation is re-
uired for stable platelet cohesion because only platelet
ound with platelet, but not with the matrix surface was
usceptible to the second perfusion of blood containing one
f the anti-GP IIb/IIIa agents. Further studies using our
ssay system, including the clarification of the relative
mportance of other factors, such as CD40 ligand (32) and
-selectin (33), are under way.
ossible mechanism. We propose the following mecha-
ism to explain how platelet thrombi are dissolved by
nti-GP IIb/IIIa agents (Fig. 6); however, please note that
he mechanism shown in Figure 6 is purely speculative.
irst, we speculate that the binding of crucial ligands,
hether VWF or fibrinogen, is reversible; therefore, ligand
olecules can be replaced by anti-GP IIb/IIIa agents when
hrombi are perfused with blood containing these agents.
latelets begin to get detached from the thrombi when the
let thrombi formed on the collagen surface. The experiments were performed
ither containing or not containing anti-GP IIb/IIIa (abciximab: 10 g/ml,
hich platelet thrombi had already formed as a result of previous perfusion of
projection images from the top [A], 45° position from the x axis [B], and the
aining one of the anti-GP IIb/IIIa agents of abciximab (I) are shown in the
licated experiments. No differences in effects were observed among the three
nts were observed when blood anticoagulated with heparin was used. For the
the July 21 issue of JACC at www.cardiosource.com/jacc.html.igure 4. Effect of anti-glycoprotein (GP) IIb/IIIa agents on the dissolution of plate
s described in the legend for Figure 1B. Blood anticoagulated with Argatroban e
ptifibatide: 0.5 M, tirofiban 0.5 M) was perfused on the collagen surface on w
ontrol blood. The three-dimensional projection images of the platelet thrombi (the
ide [C]) before and after the second perfusion of blood containing (II) or not cont
eft and right panel of I and II. The results are representative of those of eight rep
nti-GP IIb/IIIa agents tested. No differences in the effects of anti-GP IIb/IIIa age
ccompanying videos corresponding to Figure 4 (Videos 4, 5, 6, and 7), please seeigure 5. Effect of anti-glycoprotein (GP) IIb/IIIa agents on platelet
hrombi formed on the collagen surface. The experiments were performed
n a manner similar to that described in the legend for Figures 1 and 4. The
hree-dimensional structure of the platelet thrombi formed on the collagen
urface after 6-min perfusion of blood on the collagen surface at 1,500 s1
as quantified by calculating the cross-sectional areas of the platelet
hrombi using the National Institutes of Health image software at every 3
m from the collagen surface. The results are expressed as a percentage of
he largest cross-sectional area obtained at the collagen surface level. The
esults shown are the mean and standard error of eight replicated
xperiments. Similar results were obtained in the condition when blood was
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July 21, 2004:316–23 Thrombus Dissolution by Anti-GP IIb/IIIarucial number of ligand molecules necessary to maintain
he integrity of the thrombi is replaced by anti-GP IIb/IIIa
gents, and the power generated by the binding of ligands to
P IIb/IIIa is no longer sufficient to resist the shear force
enerated by blood flow. Other adhesive proteins, including
-selectin (33) and CD40 ligand (32), may be involved in
tabilizing platelet thrombi, but their roles were not inves-
igated in the present study.
dvantages and limitation of our methods. Our newly
eveloped three-dimensional analysis system depended on the
nique features of the confocal microscopy system (26). How-
ver, there were still obvious methodological limitations in our
ssay system, especially when seeking to apply the experimental
esults to understand the events in vivo. Obviously, we could
ot reproduce the complex in vivo arterial flow conditions (34)
n our flow chamber system. Under the complex flow condi-
ions prevailing in vivo, including low, high, or changing shear
Table 1. Effects of Subsequent Perfusion of Bl
Agents on the Height and the Volume of the
Before the
Second
Perfusion† C
Height of thrombi (m) 8  2 1
Volume of thrombi (m3) 3,352  1,045 7,45
*The height and the volume of the platelet thrombi before an
abciximab (10 g/ml), eptifibatide (0.5 M), or tirofiban (0.5
of the second perfusion. ‡After completion of the second per
§Values after completion of the second perfusion of blood co
that the difference compared with the value determined befo
GP  glycoprotein.
igure 6. Speculative mechanism explaining the thrombus-dissolving effect
echanism by which anti-GP IIb/IIIa agents dissolve platelet thrombi form
VWF), in addition to fibrinogen, also plays some role in stabilizing plate
o be perfused, ligand bound with activated GP IIb/IIIa was replaced by the
hen a certain number of ligands were replaced by anti-GP IIb/IIIa andntegrity of the thrombi. Details are explained in the “Discussion” section.ate conditions, the ability of anti-GP IIb/IIIa agents to
issolve platelet thrombi might be greater or lesser than that
hown in our experiments. We also conducted the experiments
t room temperature rather than at body temperature (37°C),
ostly because the thrombi were more prominent, and the
olume of blood necessary for thrombus formation was smaller
t room temperature (28). Nevertheless, the important message
hat anti-GP IIb/IIIa agents can cause dissolution of platelet
hrombi by adversely affecting platelet cohesion is not likely to
e influenced by these methodological limitations.
One might argue that the ability of anti-GP IIb/IIIa
gents to dissolve platelet thrombi in vivo might be weaker
han that shown in our experiment, because fibrin forma-
ion, which plays a crucial role in stabilizing thrombi, was
nhibited under our study conditions. The mass of platelet
hrombi detached from the body of the platelet thrombi we
ave detected herein, might also be unstable without fibrin
Containing One of the Anti-GP IIb/IIIa
xisting Platelet Thrombi*
After the Second Perfusion§
ol‡ Abciximab Eptifibatide Tirofiban
4 3  1 3  2 3  1
1,825 778  102 812  122 856  144
the second perfusion of blood containing or not containing
are shown. †Values immediately before the commencement
of blood not containing any of the anti-GP IIb/IIIa agents.
g any one of abciximab, eptifibatide, or tirofiban. Indicates
second perfusion was significant.
nti-glycoprotein (GP) IIb/IIIa agents. This figure summarizes the possible
n a collagen surface, although it is not clear whether von Willebrand factor
rombi. When blood containing one of the anti-GP IIb/IIIa agents began
P IIb/IIIa agent. Parts of the platelet thrombi started to become detached
rength of the GP IIb/IIIa ligation was no longer sufficient to support theood
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ontr
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Thrombus Dissolution by Anti-GP IIb/IIIa July 21, 2004:316–23nd may dissociate into small aggregates incapable of
mbolization. Nonetheless, our experimental results might
ave in vivo relevance because anti-GP IIb/IIIa agents tend
o be used in combination with anticoagulant and throm-
olytic therapy, which dissolve fibrin net. Indeed, we have
hown that the dissolution effects of anti-GP IIb/IIIa agents
ould still be seen when blood was anticoagulated by
eparin at concentration achieved with clinical use.
Another important issue we could not completely address in
his paper was the effects of time on the stability of platelet
hrombi. Indeed, we could not demonstrate whether the
issolution effects we described herein still occurred when the
ubsequent perfusion of blood containing anti-GP IIb/IIIa
gents was started hours after the formation of platelet
hrombi. This issue is relevant because the binding of fibrin-
gen to activated GP IIb/IIIa was reported to be reversible
nitially and became irreversible later (35). We could not
onduct experiments to answer this question directly, because
ontinuous perfusion, which prevents the falling of leukocytes
nto the platelet thrombi because of gravity, was necessary to
nsure exclusion of the possible effects of leukocytes on the
tability of the platelet thrombi. The dissolution effects of
nti-GP IIb/IIIa agents, although not exactly demonstrated as
escribed in this study, could be seen even when the subse-
uent perfusion of blood containing anti-GP IIb/IIIa agents
tarted to be perfused after 30 min from the end of initial blood
erfusion (data not shown).
onclusions. We have previously shown that different
nti-GP IIb/IIIa agents might have different effects on
latelet activation under high shear stress condition (36,37).
lthough there is still ongoing debate on whether or not
ifferent anti-GP IIb/IIIa agents have different antithrom-
otic effects in vivo (24,38), it would be reasonable to
uppose that all three anti-GP IIb/IIIa agents have similar
ffects on thrombus dissolution when used in doses required
o block platelet aggregation. In conclusion, we have dem-
nstrated the dissolution effects of various anti-GP IIb/IIIa
gents on platelet thrombi formed on the collagen surface
nder blood flow conditions.
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